<DOC>
	<DOCNO>NCT02553785</DOCNO>
	<brief_summary>This study multi-center , prospective , single-armed , study design evaluate safety efficacy BioVentrix Revivent TransCatheter ( TC ) System leave ventricular ( LV ) volume reduction heart failure ( HF ) .</brief_summary>
	<brief_title>Clinical Study BioVentrix Revivent TC Treatment Ischemic Cardiomyopathy</brief_title>
	<detailed_description>The purpose prospective , single-armed , multi-center clinical trial establish feasibility use BioVentrix Revivent TC System treatment leave ventricular dysfunction appropriate cohort human suffer heart failure . The objective study determine safety functionality device enable leave ventricle ( LV ) volume radius reduction scar exclusion appropriate patient suffer systolic HF . Use device replicates geometric reconfiguration ventricle achieve surgical Left Ventricular Reconstruction ( LVR ) , beat heart , create option eliminate use Cardiopulmonary Bypass . The System utilizes anchor implant scarred portion heart , render ventricle small , employed cardiac surgical setting without use cardiopulmonary bypass . The Revivent TC anchor may implant sternotomy mini-thoracotomy jugular access . Eligible subject limit whose ventricular dysfunction due ischemic cardiomyopathy cause , previous ( great 90 day ) myocardial infarction ( MI ) acontractile ( akinetic and/or dyskinetic ) scar locate antero-septal , apical ( may extend laterally ) region .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Age 18 80 ; Left Ventricular Ejection Fraction ( LVEF ) &gt; 15 % ≤ 45 % ; New York Heart Association ( NYHA ) Functional Class IIIV ; Left Ventricular End Systolic Volume ( LVESVI ) ≥60 cc/m² ≤ 120 cc/ m² Contiguous acontractile ( akinetic and/or dyskinetic ) scar locate anteroseptal , apical ( may extend laterally ) region leave ventricle evidence Cardiac Magnetic Resonance ( CMR ) Computed Tomography ( CT ) ; Maintained standard medical management least 90 day , stable target ( maximum tolerate ) dosage ; Willing competent complete inform consent ; Viability myocardium region remote area intend scar exclusion evidence CMR CT ; Agree require followup visit Calcified ventricular wall area intend scar exclusion verify echocardiography equivalent ; Thrombus intraventricular mass leave atrium ventricle verify echocardiography equivalent ; Cardiac Resynchronization Therapy ( CRT ) device placement ≤ 60 day prior enrollment ; Significant diastolic dysfunction , define pseudonormal Doppler filling pattern E/A ratio &gt; 2 ; Thin wall , paradoxically move septal scar would preclude successful support anchor pair evidence CMR ; Cardiac valve disease , opinion investigator , require surgery ; Intolerance unwillingness take anticoagulation medication ; Functioning pacemaker lead anteroapical right ventricle , , opinion investigator , would interfere anchor placement ; Pulmonary Arterial Pressure &gt; 60 mm Hg via echo ; Myocardial Infarction within 90 day prior enrollment ; Previous Cerebrovascular Accident ( CVA ) Transient Ischemic Attack ( TIA ) result , opinion investigator , significant residual neurological deficit ; Aorto iliac disease would preclude femfem bypass . Previous right neck surgery , previous pericardiotomy , previous leave chest surgery ; Comorbid disease process life expectancy le one year ; Patients lung , kidney and/or liver transplant ; Chronic renal failure serum creatinine &gt; 2 mg/dL ; Inoperable coronary disease significant ischemia ; Pregnant planning become pregnant study ; Enrolled concurrent study observational . Previous leave thoracotomy Pulmonary disease would preclude single lung ventilation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>BioVentrix</keyword>
	<keyword>Revivent</keyword>
	<keyword>Revivent TC</keyword>
</DOC>